Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12055333 | 0.87 | TDP1 (0.37) | TDP1KDM4EFFAR1CPT2ADRA1A | |
| SCHEMBL667039 | 0.85 | KDM4E (0.38) | TDP1KDM4EFFAR1CPT2ADRA1A | |
| SCHEMBL7841654 | 0.84 | GAA (0.46) | TDP1KDM4EFFAR1CPT2ADRA1A | |
| SCHEMBL1506890 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506857 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506836 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506852 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506826 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506885 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA | |
| SCHEMBL1506838 | 0.83 | NAAA (0.56) | TDP1FFAR1CPT2TSHRDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | DCLRE1A, RNGTT, NSUN2 | TDP1 1327/4885KDM4E 2187/4885FFAR1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.